Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, Pessayre D
Unité de Recherches de Physiopathologie Hépatique (INSERM U 24), Hôpital Beaujon, Clichy, France.
Br J Clin Pharmacol. 1987 Nov;24(5):676-9. doi: 10.1111/j.1365-2125.1987.tb03230.x.
Genetically-controlled drug oxidation capacity was studied using dextromethorphan, an anti-tussive drug, as the test compound in 103 healthy white French subjects (61 males and 42 females). Phenotyping was performed using the metabolic ratio (MR) calculated as MR = 0-10 h urinary output of dextromethorphan/0-10 h urinary output of dextrorphan, after oral administration of 40 mg (113.6 mumol) of dextromethorphan hydrobromide. The log MR was bimodally distributed: 99 subjects (96.1%) were phenotyped as extensive metabolizers; they had a log MR between -3.1 and -1.1, a urinary output of dextromethorphan below 5 mumol 10 h-1 and a urinary output of dextrorphan above 20 mumol 10 h-1. Four subjects (3.9%) were phenotyped as poor metabolizers; they had a log MR between -0.5 and +0.7, a urinary output of dextromethorphan above 5 mumol 10 h-1 and a urinary out of dextrorphan below 20 mumol 10 h-1.
以止咳药右美沙芬作为测试化合物，对103名健康的法国白人受试者（61名男性和42名女性）的基因控制药物氧化能力进行了研究。口服40毫克（113.6微摩尔）氢溴酸右美沙芬后，使用代谢比（MR）进行表型分析，代谢比的计算方法为MR = 右美沙芬0至10小时尿量/右啡烷0至10小时尿量。对数MR呈双峰分布：99名受试者（96.1%）被表型为快代谢者；他们的对数MR在-3.1至-1.1之间，右美沙芬尿量低于5微摩尔/10小时，右啡烷尿量高于20微摩尔/10小时。4名受试者（3.9%）被表型为慢代谢者；他们的对数MR在-0.5至+0.7之间，右美沙芬尿量高于5微摩尔/10小时，右啡烷尿量低于20微摩尔/10小时。
